Mapping of serological testing and SARS-CoV-2 seroprevalence studies performed in 20 European countries, March-June 2020.
Journal
Journal of global health
ISSN: 2047-2986
Titre abrégé: J Glob Health
Pays: Scotland
ID NLM: 101578780
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
19
8
2021
pubmed:
20
8
2021
medline:
21
8
2021
Statut:
epublish
Résumé
The SARS-CoV-2 pandemic spread across Europe from February 2020. While robust SARS-CoV-2 serological assays were quickly developed, only limited information on applied serological testing is available. We describe the extent and nature of SARS-CoV-2 serological testing used in Europe and assess the links between epidemiology, mitigation strategies applied and seroprevalence. An online questionnaire on SARS-CoV-2 serology was sent to the European Society of Clinical Virology and European Non-Polio Enterovirus Network members in September 2020. Data were analysed by comparing mitigation approaches, serological methods and seroprevalance studies performed. About 100 000 laboratory confirmed cases identified between March and June 2020 were reported by 36 participating laboratories from 20 countries. All responders experienced mitigation strategies including lockdowns and other closures. All except one participant had introduced serological testing; most had validated their assays (n = 29), but some had had difficulties in obtaining reference material. Most used commercial assays (n = 35), measuring IgG response against the spike antigen. Serology was used primarily for diagnostic purposes (n = 22) but also for convalescent plasma (n = 13) and research studies (n = 30). Seroprevalence studies targeted mainly health care workers (n = 20; seroprevalance 5% to 22%) and general population (n = 16; seroprevalance 0.88% to 5.6%). Basic demographic and clinical information were collected by most laboratories (n = 28), whereas data on long-term outcomes were rarely collected. This is first study gathering systematic information on serological testing approaches implemented during the first pandemic wave in Europe.
Sections du résumé
BACKGROUND
BACKGROUND
The SARS-CoV-2 pandemic spread across Europe from February 2020. While robust SARS-CoV-2 serological assays were quickly developed, only limited information on applied serological testing is available. We describe the extent and nature of SARS-CoV-2 serological testing used in Europe and assess the links between epidemiology, mitigation strategies applied and seroprevalence.
METHODS
METHODS
An online questionnaire on SARS-CoV-2 serology was sent to the European Society of Clinical Virology and European Non-Polio Enterovirus Network members in September 2020. Data were analysed by comparing mitigation approaches, serological methods and seroprevalance studies performed.
RESULTS
RESULTS
About 100 000 laboratory confirmed cases identified between March and June 2020 were reported by 36 participating laboratories from 20 countries. All responders experienced mitigation strategies including lockdowns and other closures. All except one participant had introduced serological testing; most had validated their assays (n = 29), but some had had difficulties in obtaining reference material. Most used commercial assays (n = 35), measuring IgG response against the spike antigen. Serology was used primarily for diagnostic purposes (n = 22) but also for convalescent plasma (n = 13) and research studies (n = 30). Seroprevalence studies targeted mainly health care workers (n = 20; seroprevalance 5% to 22%) and general population (n = 16; seroprevalance 0.88% to 5.6%). Basic demographic and clinical information were collected by most laboratories (n = 28), whereas data on long-term outcomes were rarely collected.
CONCLUSIONS
CONCLUSIONS
This is first study gathering systematic information on serological testing approaches implemented during the first pandemic wave in Europe.
Identifiants
pubmed: 34408857
doi: 10.7189/jogh.11.05014
pii: jogh-11-05014
pmc: PMC8364255
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
05014Informations de copyright
Copyright © 2021 by the Journal of Global Health. All rights reserved.
Déclaration de conflit d'intérêts
Competing interests: The authors completed the ICME Unified Competing Interest form (available upon request from the corresponding author) and declare no conflict of interest.
Références
Euro Surveill. 2020 Feb;25(5):
pubmed: 32046819
Clin Infect Dis. 2021 Jun 1;72(11):e695-e703
pubmed: 32945846
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Nat Commun. 2020 Nov 12;11(1):5744
pubmed: 33184284
Clin Chem Lab Med. 2020 Aug 27;58(12):2121-2130
pubmed: 32853163
J Clin Invest. 2020 Dec 1;130(12):6477-6489
pubmed: 32833687
Lancet Reg Health Eur. 2021 Feb;1:100013
pubmed: 34173621
Clin Microbiol Infect. 2021 Jul;27(7):1039.e1-1039.e7
pubmed: 33838303
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
JAMA. 2020 May 26;323(20):2085-2086
pubmed: 32293646
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Emerg Microbes Infect. 2020 Dec;9(1):680-686
pubmed: 32207377
Microorganisms. 2020 Oct 13;8(10):
pubmed: 33066057
BMJ. 2020 Jul 1;370:m2516
pubmed: 32611558
Transfus Med. 2021 Jun;31(3):167-175
pubmed: 33333627
Am J Kidney Dis. 2020 Sep;76(3):440-441
pubmed: 32512038